Xromi safety study for children under 2 with sickle cell disease
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study is checking how safe and effective Xromi is for babies and toddlers (under 2 years old) with sickle cell disease. It compares kids who take Xromi to those who don't, to see if it helps prevent problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 9 months old and under 2 years old.
- Your child must have sickle cell disease (SCD).
- Your child must be prescribed Xromi to prevent SCD complications.
- Your child must not have used hydroxycarbamide before.
- Your child must not be on regular blood transfusions (every 8 weeks or more often).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new twice-daily liquid form of hydroxyurea (a common SCD medicine) in children ages 9 months to 11 years with sickle cell disease. It will check how the medicine works in the body, if it is safe, and if it helps reduce pain crises and other complications.
This study tests a medicine called crizanlizumab to see if it helps improve oxygen delivery in people with sickle cell anemia. It may help reduce pain crises and other complications.
This trial tests an investigational drug called DISC-3405 in people with sickle cell disease (SCD) to see if it is safe and how it affects your body. It may be an option if you have certain SCD complications or lab results.
This study tests a new medicine called anumigilimab to see if it is safe for people with sickle cell disease. The study focuses on those who have had pain crises recently, to help manage and prevent them.
This study tests a way to do a bone marrow (stem cell) transplant from an HLA-matched sibling in children with sickle cell disease, aiming to lower the risk of serious side effects. You may be considered if you have certain past sickle complications and your body can safely handle the transplant plan.
This trial tests a drug called motixafortide that helps move stem cells from your bone marrow into your blood so they can be collected for future gene therapy. It is for adults with severe sickle cell disease who may benefit from this treatment approach.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.